This $483,852 Project Grant award was provided by the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837). The award will fund the development of a high-throughput platform technology to measure the equilibrium and kinetics of hemoglobin polymerization in individual red blood cells. This platform will enable the assessment of new sickle cell disease treatments that aim to reduce intracellular hemoglobin polymer formation, which is a key driver of the disease. The grantee, The General Hospital Corporation (doing business as Massachusetts General Hospital), will use this platform to characterize the hemoglobin polymerization process across different sickle cell disease phenotypes and in response to variations in hemoglobin concentration and other factors. This new measurement capability is expected to support the development, optimization, and clinical implementation of emerging sickle cell disease therapies.